CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2024

Dec 11, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2024-12-09

Reporting Person: Miller Steve (Chief Op. & Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-09	Common stock, par value $0.001 per share	M	11872	—	Acquired	686996	Direct
2024-12-10	Common stock, par value $0.001 per share	M	50000	$4.01	Acquired	736996	Direct
2024-12-10	Common stock, par value $0.001 per share	S	50000	$21.927	Disposed	686996	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-09	Restricted Stock Units	$	M	11872	Disposed		Common Stock (11872)	Direct
2024-12-10	Options to purchase common stock	$4.01	M	50000	Disposed	2025-01-02	Common Stock (50000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

F2: Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.

F3: Represents a weighted average price for the shares sold. Shares were sold in a range between $21.73 and $22.09 per share.

F4: Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026.

F5: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 9, 2024.

F6: Options vested in three annual tranches beginning on January 2, 2019.